Evaluation	O
of	O
Cardiac	B:C0876994
Toxicity	I:C0876994
Biomarkers	B:C0005516
in	O
Rats	B:C0034693
from	O
Different	O
Laboratories	B:C0022877
.	O

There	O
is	O
a	O
great	O
need	O
for	O
improved	B:C0184511
diagnostic	O
and	O
prognostic	B:C0220901
accuracy	O
of	O
potential	O
cardiac	B:C0876994
toxicity	I:C0876994
in	O
drug	B:C0872152
development	I:C0872152
.	O

This	O
study	B:C2603343
reports	B:C0011000
the	O
evaluation	O
of	O
several	O
commercially	O
available	O
biomarker	B:C0005516
kits	I:C0005516
by	O
3	O
institutions	B:C2607850
(	O
SRI	B:C2607850
,	O
Eli	O
Lilly	O
,	O
and	O
Pfizer	O
)	O
for	O
the	O
discrimination	O
between	O
myocardial	B:C0027046
degeneration	I:C0027046
/	O
necrosis	B:C1442837
and	O
cardiac	B:C1383860
hypertrophy	I:C1383860
as	O
well	O
as	O
the	O
assessment	O
of	O
the	O
interlaboratory	O
and	O
interplatform	O
variation	O
in	O
results	O
.	O

Serum	O
concentrations	O
of	O
natriuretic	B:C1144709
peptides	I:C1144709
(	O
N	B:C0027481
-	I:C0027481
terminal	I:C0027481
pro-atrial	I:C0027481
natriuretic	I:C0027481
peptide	I:C0027481
[	O
N	B:C0027481
-	I:C0027481
terminal	I:C0027481
pro-atrial	I:C0027481
natriuretic	I:C0027481
peptide	I:C0027481
]	O
and	O
N	B:C0754710
-	I:C0754710
terminal	I:C0754710
pro-brain	I:C0754710
natriuretic	I:C0754710
peptide	I:C0754710
[	O
N	B:C0754710
-	I:C0754710
terminal	I:C0754710
pro-brain	I:C0754710
natriuretic	I:C0754710
peptide	I:C0754710
]	O
)	O
,	O
cardiac	B:C0018787
and	O
skeletal	B:C0521324
troponins	B:C0041199
(	O
cardiac	B:C1305957
and	I:C1305957
skeletal	I:C1305957
troponins	I:C1305957
,	O
cTnT	B:C3538889
,	O
and	O
sTnI	B:C0033684
)	O
,	O
myosin	B:C0027108
light	I:C0027108
chain	I:C0027108
3	I:C0027108
(	O
myosin	B:C0027108
light	I:C0027108
chain	I:C0027108
3	I:C0027108
)	O
,	O
and	O
fatty	B:C1721418
acid	I:C1721418
binding	I:C1721418
protein	I:C1721418
3	I:C1721418
(	O
fatty	B:C1721418
acid	I:C1721418
binding	I:C1721418
protein	I:C1721418
3	I:C1721418
)	O
were	O
assessed	O
in	O
rats	B:C0034693
treated	O
with	O
minoxidil	B:C0026196
(	O
minoxidil	B:C0026196
)	O
and	O
isoproterenol	B:C0022245
(	O
isoproterenol	B:C0022245
)	O
.	O

minoxidil	B:C0026196
caused	O
increased	O
heart	B:C0018787
-	O
to	O
-	O
body	O
weight	O
ratios	O
and	O
prominent	O
elevations	B:C0702240
in	O
N	B:C0027481
-	I:C0027481
terminal	I:C0027481
pro-atrial	I:C0027481
natriuretic	I:C0027481
peptide	I:C0027481
and	O
N	B:C0754710
-	I:C0754710
terminal	I:C0754710
pro-brain	I:C0754710
natriuretic	I:C0754710
peptide	I:C0754710
concentrations	O
detected	B:C0442726
at	O
24	O
-	O
hr	O
postdose	O
without	O
elevation	B:C0702240
in	O
troponins	B:C0041199
,	O
myosin	B:C0027108
light	I:C0027108
chain	I:C0027108
3	I:C0027108
,	O
or	O
fatty	B:C1721418
acid	I:C1721418
binding	I:C1721418
protein	I:C1721418
3	I:C1721418
and	O
with	O
no	B:C1513916
abnormal	B:C0205161
histopathological	O
findings	B:C0243095
.	O

isoproterenol	B:C0022245
caused	O
ventricular	B:C1522565
leukocyte	B:C0333361
infiltration	I:C0333361
,	O
myocyte	B:C0151654
fibrosis	I:C0151654
,	O
and	O
necrosis	B:C0027540
with	O
increased	O
concentrations	O
of	O
the	O
natriuretic	B:C1144709
peptides	I:C1144709
,	O
cardiac	B:C0018787
troponins	B:C0041199
,	O
and	O
myosin	B:C0027108
light	I:C0027108
chain	I:C0027108
3	I:C0027108
.	O

These	O
results	O
reinforce	O
the	O
advantages	O
of	O
a	O
multimarker	O
strategy	O
in	O
elucidating	O
the	O
underlying	O
cause	O
of	O
cardiac	B:C0018799
insult	I:C0018799
and	O
detecting	B:C0442726
myocardial	B:C0027061
tissue	B:C0010957
damage	I:C0010957
at	O
24	O
-	O
hr	O
posttreatment	O
.	O

The	O
interlaboratory	O
and	O
interplatform	O
comparison	O
analyses	B:C0936012
also	O
showed	O
that	O
the	O
data	O
obtained	O
from	O
different	O
laboratories	B:C0022877
and	O
platforms	O
are	O
highly	O
correlated	O
and	O
reproducible	O
,	O
making	O
these	O
biomarkers	B:C0005516
widely	O
applicable	O
in	O
preclinical	B:C1709631
studies	I:C1709631
.	O

